IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Log in (now much improved!)

Citations for "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry"

by Daron Acemoglu & Joshua Linn

For a complete description of this item, click here. For a RSS feed for citations of this item, click here.
as in new window

  1. Shang-Jin Wei & Zhuan Xie & Xiaobo Zhang, 2016. "From “Made in China” to “Innovated in China”: Necessity, Prospect, and Challenges," NBER Working Papers 22854, National Bureau of Economic Research, Inc.
  2. Mueller-Langer, Frank, 2011. "Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting research?," MPRA Paper 40193, University Library of Munich, Germany.
  3. James D. Adams, 2005. "Industrial R&D Laboratories: Windows on Black Boxes?," The Journal of Technology Transfer, Springer, vol. 30(2_2), pages 129-137, 01.
  4. Iain Cockburn & Jean O. Lanjouw & Mark Schankerman, 2014. "Patents and the global diffusion of new drugs," LSE Research Online Documents on Economics 60450, London School of Economics and Political Science, LSE Library.
  5. Kahn Matthew E & Vaughn Ryan K., 2009. "Green Market Geography: The Spatial Clustering of Hybrid Vehicles and LEED Registered Buildings," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 9(2), pages 1-24, March.
  6. Amy Finkelstein, 2005. "The Aggregate Effects of Health Insurance: Evidence from the Introduction of Medicare," NBER Working Papers 11619, National Bureau of Economic Research, Inc.
  7. Bhattacharya, Jay & Packalen, Mikko, 2011. "Opportunities and benefits as determinants of the direction of scientific research," Journal of Health Economics, Elsevier, vol. 30(4), pages 603-615, July.
  8. Mikko Packalen, 2011. "Market Share Exclusion," Working Papers 1103, University of Waterloo, Department of Economics, revised Aug 2011.
  9. Bergh, Andreas & Nilsson, Therese, 2012. "When More Poor Means Less Poverty: On Income Inequality and Purchasing Power," Working Paper Series 900, Research Institute of Industrial Economics.
  10. Timo Boppart & Franziska J. Weiss, 2012. "Structural Change, Market Size and Sector Specific Endogenous Growth," DEGIT Conference Papers c017_062, DEGIT, Dynamics, Economic Growth, and International Trade.
  11. Pierre M. Picard, 2012. "Trade, Economic Geography and the Choice of Product Quality," CREA Discussion Paper Series 12-11, Center for Research in Economic Analysis, University of Luxembourg.
  12. Fidel Pérez Sebastián, 2011. "Understanding R&D Policy: Efficiency or Politics?," Working Papers. Serie AD 2011-17, Instituto Valenciano de Investigaciones Económicas, S.A. (Ivie).
  13. Chad Syverson, 2011. "What Determines Productivity?," Journal of Economic Literature, American Economic Association, vol. 49(2), pages 326-65, June.
  14. Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Chapters, in: Innovation Policy and the Economy, Volume 16 National Bureau of Economic Research, Inc.
  15. Reto Foellmi & Josef Zweim�ller, . "Income Distribution and Demand-induced Innovations," IEW - Working Papers 212, Institute for Empirical Research in Economics - University of Zurich.
  16. Ashish Arora & Alfonso Gambardella & Laura Magazzini & Fabio Pammolli, 2009. "A Breath of Fresh Air? Firm Type, Scale, Scope and Selection Effects in Drug Development," KITeS Working Papers 003, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised Mar 2009.
  17. Daron Acemoglu & David Cutler & Amy Finkelstein & Joshua Linn, 2006. "Did Medicare Induce Pharmaceutical Innovation?," American Economic Review, American Economic Association, vol. 96(2), pages 103-107, May.
  18. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Starving (or Fattening) the Golden Goose?: Generic Entry and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
  19. zhibo Tan & Xiaobo Zhang, 2016. "Does Female Labor Scarcity Encourage Innovation? Evidence from China’s Gender Imbalance," Working Papers id:11039, eSocialSciences.
  20. Kristopher J. Hult & Tomas J. Philipson, 2012. "Public Liabilities and Health Care Policy," NBER Working Papers 18571, National Bureau of Economic Research, Inc.
  21. Magazzini Laura & Fabio Pammolli, 2013. "R&D, Within and Between Patent Competition in the Pharmaceutical Industry," Working Papers 3/2013, IMT Institute for Advanced Studies Lucca, revised Jul 2013.
  22. Coelli, Federica & Moxnes, Andreas & Ulltveit-Moe, Karen-Helene, 2016. "Better, Faster, Stronger: Global Innovation and Trade Liberalization," CEPR Discussion Papers 11506, C.E.P.R. Discussion Papers.
  23. William R. Kerr & William F. Lincoln, 2008. "The Supply Side of Innovation: H-1B Visa Reforms and US Ethnic Invention," Harvard Business School Working Papers 09-005, Harvard Business School.
  24. L. Rachel Ngai & Roberto M. Samaniego, 2009. "Accounting for Research and Productivity Growth Across Industries," CEP Discussion Papers dp0914, Centre for Economic Performance, LSE.
  25. Mikko Packalen & Jay Bhattacharya, 2010. "The Other Ex-Ante Moral Hazard in Health," Working Papers 1015, University of Waterloo, Department of Economics, revised Dec 2010.
  26. Chee-Ruey Hsieh & Ya-Ming Liu & Chia-Lin Chang, 2013. "Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 287-295, April.
  27. Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2014. "The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India," NBER Working Papers 20548, National Bureau of Economic Research, Inc.
  28. Entorf, Horst & Fegert, Jörg & Kölch, Michael, 2004. "Children in Need of Medical Innovation," Darmstadt Discussion Papers in Economics 135, Darmstadt University of Technology, Department of Law and Economics.
  29. Stern, Ariel Dora, 2017. "Innovation under regulatory uncertainty: Evidence from medical technology," Journal of Public Economics, Elsevier, vol. 145(C), pages 181-200.
  30. Aghion, Philippe & Dechezleprêtre, Antoine & Hemous, David & Martin, Ralf & Van Reenen, John, 2012. "Carbon Taxes, Path Dependency and Directed Technical Change: Evidence from the Auto Industry," CEPR Discussion Papers 9267, C.E.P.R. Discussion Papers.
  31. repec:bof:bofrdp:urn:nbn:fi:bof-201512141480 is not listed on IDEAS
  32. Pammolli, Fabio & Riccaboni, Massimo, 2004. "Market Structure and Drug Innovation," MPRA Paper 16212, University Library of Munich, Germany.
  33. Ryo Horii, 2006. "Wants and Past Knowledge: Growth Cycles with Emerging Industries," Discussion Papers in Economics and Business 06-03, Osaka University, Graduate School of Economics and Osaka School of International Public Policy (OSIPP).
  34. Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2012. "I Farmaci Oncologici in Italia: innovazione e sostenibilità economica," Working Papers 02-2012, Competitività Regole Mecati (CERM).
  35. Ulrike Malmendier & Stefan Nagel, 2009. "Depression Babies: Do Macroeconomic Experiences Affect Risk-Taking?," NBER Working Papers 14813, National Bureau of Economic Research, Inc.
  36. Michael Kremer & Heidi Williams, 2010. "Incentivizing Innovation: Adding to the Tool Kit," NBER Chapters, in: Innovation Policy and the Economy, Volume 10, pages 1-17 National Bureau of Economic Research, Inc.
  37. Malani, Anup & Reif, Julian, 2015. "Interpreting pre-trends as anticipation: Impact on estimated treatment effects from tort reform," Journal of Public Economics, Elsevier, vol. 124(C), pages 1-17.
  38. Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
  39. Amitabh Chandra & Jonathan Skinner, 2012. "Technology Growth and Expenditure Growth in Health Care," Journal of Economic Literature, American Economic Association, vol. 50(3), pages 645-80, September.
  40. Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
  41. Anirban Basu & David Meltzer, 2012. "Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials," PharmacoEconomics, Springer, vol. 30(10), pages 859-868, October.
  42. Darius Lakdawalla & Neeraj Sood, 2007. "The Welfare Effects of Public Drug Insurance," NBER Working Papers 13501, National Bureau of Economic Research, Inc.
  43. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
  44. Christian Jaag, 2013. "Intellectual Property Rights and the Future of Universal Service Obligations in Communications," Working Papers 0040, Swiss Economics.
  45. Moshe Levy & Adi Rizansky, 2014. "Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 143-156, March.
  46. Matthew E. Kahn, 2014. "Climate Change Adaptation: Lessons from Urban Economics," NBER Working Papers 20716, National Bureau of Economic Research, Inc.
  47. Zheng, Siqi & Wu, Jing & Kahn, Matthew E. & Deng, Yongheng, 2012. "The nascent market for “green” real estate in Beijing," European Economic Review, Elsevier, vol. 56(5), pages 974-984.
  48. Philippe Aghion & Peter Howitt & Susanne Prantl, 2015. "Patent rights, product market reforms, and innovation," Journal of Economic Growth, Springer, vol. 20(3), pages 223-262, September.
  49. Gary S. Becker & Kevin M. Murphy, 2007. "Education and Consumption: The Effects of Education in the Household Compared to the Marketplace," Journal of Human Capital, University of Chicago Press, vol. 1(1), pages 9-35.
  50. Anupam Jena & Casey Mulligan & Tomas J. Philipson & Eric Sun, 2008. "The Value of Life in General Equilibrium," NBER Working Papers 14157, National Bureau of Economic Research, Inc.
  51. Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
  52. Saint-Paul, Gilles, 2004. "To What Extent should less Developed Countries Enforce Intellectual Property?," IDEI Working Papers 336, Institut d'Économie Industrielle (IDEI), Toulouse.
  53. Rutger P. Daems PhD & Edith L. Maes DBA, 2013. "Pharmaceutical Portfolio Management: Global Disease Burden and Corporate Performance Metrics," Working Papers 2013/07, Maastricht School of Management.
  54. Viktor Slavtchev & Simon Wiederhold, 2011. "The Impact of Government Procurement Composition on Private R&D Activities," Jena Economic Research Papers 2011-036, Friedrich-Schiller-University Jena.
  55. Acemoglu, Daron & Finkelstein, Amy & Notowidigdo, Matthew J., 2009. "Income and Health Spending: Evidence from Oil Price Shocks," CEPR Discussion Papers 7255, C.E.P.R. Discussion Papers.
  56. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(02), pages 185-208, April.
  57. Timo Boppart & Franziska J. Weiss, 2013. "Non-homothetic preferences and industry directed technical change," ECON - Working Papers 123, Department of Economics - University of Zurich.
  58. Casey B. Mulligan & Kevin K. Tsui, 2006. "Political Competitiveness," NBER Working Papers 12653, National Bureau of Economic Research, Inc.
  59. Simon Wiederhold, 2012. "The Role of Public Procurement in Innovation: Theory and Empirical Evidence," ifo Beiträge zur Wirtschaftsforschung, Ifo Institute - Leibniz Institute for Economic Research at the University of Munich, number 43.
  60. Xu Wang & Xiaobo Zhang & Zhuan Xie & Huang Yiping, 2016. "Roads to Innovation: Firm-Level Evidence from China," Working Papers id:11121, eSocialSciences.
  61. Etro, Federico, 2008. "Growth leaders," Journal of Macroeconomics, Elsevier, vol. 30(3), pages 1148-1172, September.
  62. Michael Kremer & Christopher M. Snyder, 2013. "When Is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity," NBER Working Papers 18862, National Bureau of Economic Research, Inc.
  63. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2009. "Nuove politiche per l'innovazione nel settore delle scienze della vita," Working Papers 03-2009, Competitività Regole Mecati (CERM).
  64. Tan, Zhibo & Zhang, Xiaobo, 2016. "Does female labor scarcity encourage innovation?: Evidence from China’s gender imbalance," IFPRI discussion papers 1540, International Food Policy Research Institute (IFPRI).
  65. Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
  66. Frank R. Lichtenberg, 2012. "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009," NBER Working Papers 18235, National Bureau of Economic Research, Inc.
  67. Werfel, Seth H. & Jaffe, Adam B., 2013. "Induced innovation and technology trajectory: Evidence from smoking cessation products," Research Policy, Elsevier, vol. 42(1), pages 15-22.
  68. Inge van den Bijgaart, 2015. "The Unilateral Implementation of a Sustainable Growth Path with Directed Technical Change," Working Papers 2015.11, Fondazione Eni Enrico Mattei.
  69. Rzakhanov, Zaur, 2008. "Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act," Research Policy, Elsevier, vol. 37(4), pages 673-689, May.
  70. Philip Ulrich Sauré, 2015. "Time-intensive R&D and unbalanced trade," Working Papers 2015-11, Swiss National Bank.
  71. Cabral, Luís M B & Cozzi, Guido & Denicolò, Vincenzo & Spagnolo, Giancarlo & Zanza, Matteo, 2006. "Procuring Innovation," CEPR Discussion Papers 5774, C.E.P.R. Discussion Papers.
  72. Bastian Rake, 2013. "Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited," DRUID Working Papers 13-03, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
  73. Danzon, Patricia M. & Nicholson, Sean & Pereira, Nuno Sousa, 2005. "Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances," Journal of Health Economics, Elsevier, vol. 24(2), pages 317-339, March.
  74. Matthew E. Kahn & Randall Walsh, 2014. "Cities and the Environment," NBER Working Papers 20503, National Bureau of Economic Research, Inc.
  75. Philippe Aghion & David Hemous & Enisse Kharroubi, 2011. "Cyclical fiscal policy, credit constraints, and industry growth," BIS Working Papers 340, Bank for International Settlements.
  76. William R. Kerr & Ramana Nanda, 2014. "Financing Innovation," NBER Working Papers 20676, National Bureau of Economic Research, Inc.
  77. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
  78. repec:hal:wpaper:halshs-00564921 is not listed on IDEAS
  79. Margaret K. Kyle & Anita M. McGahan, 2012. "Investments in Pharmaceuticals Before and After TRIPS," The Review of Economics and Statistics, MIT Press, vol. 94(4), pages 1157-1172, November.
  80. Duggan, Mark & Goyal, Aparajita, 2012. "Pharmaceutical patents and prices : a preliminary empirical assessment using data from India," Policy Research Working Paper Series 6063, The World Bank.
  81. Anupam B. Jena & Stéphane Mechoulan & Tomas J. Philipson, 2010. "Altruism and Innovation in Health Care," Journal of Law and Economics, University of Chicago Press, vol. 53(3), pages 497 - 518.
  82. Winghan Kwong & Edward Norton, 2007. "The Effect of Advertising on Pharmaceutical Innovation," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 31(3), pages 221-236, November.
  83. Eric Helland & Seth A. Seabury, 2016. "Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges," NBER Working Papers 22194, National Bureau of Economic Research, Inc.
  84. Aghion, Philippe & Howitt, Peter & Prantl, Susanne, 2015. "Patent rights, product market reforms, and innovation," Scholarly Articles 27755230, Harvard University Department of Economics.
  85. Corinne Sauer & Robert Sauer, 2007. "Is it possible to have cheaper drugs and preserve the incentive to innovate? The benefits of privatizing the drug approval process," The Journal of Technology Transfer, Springer, vol. 32(5), pages 509-524, October.
  86. Cai, Yuezhou & Hanley, Aoife, 2012. "Building BRICS: 2-Stage DEA analysis of R&D efficiency," Kiel Working Papers 1788, Kiel Institute for the World Economy (IfW).
  87. Vives, Xavier, 2004. "Innovation and Competitive Pressure," CEPR Discussion Papers 4369, C.E.P.R. Discussion Papers.
  88. Chiara Criscuolo & Angelo Secchi, 2016. "Resources (mis)allocation, innovation and the competitiveness of Europe," Economia e Politica Industriale: Journal of Industrial and Business Economics, Springer;Associazione Amici di Economia e Politica Industriale, vol. 43(1), pages 1-9, March.
  89. Grossmann, Volker, 2013. "Do cost-sharing and entry deregulation curb pharmaceutical innovation?," Journal of Health Economics, Elsevier, vol. 32(5), pages 881-894.
  90. Toole, Andrew A., 2011. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," ZEW Discussion Papers 11-063, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
  91. van der Boor, Paul & Oliveira, Pedro & Veloso, Francisco, 2014. "Users as innovators in developing countries: The global sources of innovation and diffusion in mobile banking services," Research Policy, Elsevier, vol. 43(9), pages 1594-1607.
  92. Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
  93. Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes, 2015. "Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry," Annals of Economics and Finance, Society for AEF, vol. 16(2), pages 273-289, November.
  94. Dekker, Thijs & Vollebergh, Herman R.J. & de Vries, Frans P. & Withagen, Cees A., 2012. "Inciting protocols," Journal of Environmental Economics and Management, Elsevier, vol. 64(1), pages 45-67.
  95. David M. Cutler & Ellen Meara & Seth Richards, 2009. "Induced Innovation and Social Inequality: Evidence from Infant Medical Care," NBER Working Papers 15316, National Bureau of Economic Research, Inc.
  96. Toole, Andrew A., 2012. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 41(1), pages 1-12.
  97. Rutger P. Daems PhD & Edith L. Maes DBA & Guy Nuyts, PhD, 2013. "Advancing Pharmaceutical R&D on Neglected Diseases: Valuing Push and Pull Economic Incentive Mechanisms," Working Papers 2013/11, Maastricht School of Management.
  98. Abdulkadir Civan & Michael Maloney, 2015. "Launch Decisions of Pharmaceutical Companies," European Journal of Economic and Political Studies, Fatih University, vol. 8(2), pages 35-58.
  99. Gilad Sorek, 2013. "Efficient Self-Protection and Progress in Curing-Technology," Auburn Economics Working Paper Series auwp2013-07, Department of Economics, Auburn University.
  100. Pilar Beneito & Paz Coscollá-Girona & María Engracia Rochina-Barrachina & Amparo Sanchis, 2015. "Competitive Pressure and Innovation at the Firm Level," Journal of Industrial Economics, Wiley Blackwell, vol. 63(3), pages 422-457, 09.
  101. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484 National Bureau of Economic Research, Inc.
  102. Packalen, Mikko, 2010. "Complements and potential competition," International Journal of Industrial Organization, Elsevier, vol. 28(3), pages 244-253, May.
  103. Kelton, Christina M.L. & Rebelein, Robert P., 2005. "A General-Equilibrium Analysis of Public Policy for Pharmaceutical Prices," Vassar College Department of Economics Working Paper Series 78, Vassar College Department of Economics.
  104. Civan, Abdülkadir & Koksal, Bulent, 2007. "The Effect of Newer Drugs on Health Spending: Do They Really Increase the Costs?," MPRA Paper 6846, University Library of Munich, Germany.
  105. Shanjun Li & Matthew E. Kahn & Jerry Nickelsburg, 2014. "Public Transit Bus Procurement: The Role of Energy Prices, Regulation and Federal Subsidies," NBER Working Papers 19964, National Bureau of Economic Research, Inc.
  106. Yi-Wen Tsai & Yu-Wen Wen & Weng-Foung Huang & Ken Kuo & Pei-Fen Chen & Hsin-Wei Shih & Yue-Chune Lee, 2010. "Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 279-290, June.
  107. Beerli, Andreas & Weiss, Franziska & Zilibotti, Fabrizio & Zweimüller, Josef, 2013. "Demand Forces of Technical Change Evidence from the Chinese Manufacturing Industry," Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79980, Verein für Socialpolitik / German Economic Association.
  108. Daron Acemoglu & Amy Finkelstein, 2006. "Input and Technology Choices in Regulated Industries: Evidence From the Health Care Sector," NBER Working Papers 12254, National Bureau of Economic Research, Inc.
  109. John A. Romley & Neeraj Sood, 2013. "Identifying the Health Production Function: The Case of Hospitals," NBER Working Papers 19490, National Bureau of Economic Research, Inc.
  110. Philip Sauré, 2015. "The Resilient Trade Surplus, the Pharmaceutical Sector, and Exchange Rate Assessments in Switzerland," Working Paper Series WP15-11, Peterson Institute for International Economics.
  111. Crass, Dirk & Schwiebacher, Franz, 2013. "Do trademarks diminish the substitutability of products in innovative knowledge-intensive services?," ZEW Discussion Papers 13-061, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
  112. Alberto Galasso & Hong Luo, 2016. "Tort Reform and Innovation," NBER Working Papers 22712, National Bureau of Economic Research, Inc.
  113. Ernst R. Berndt, 2007. "A primer on the economics of re-importation of prescription drugs," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 415-435.
  114. Oliver Falck & Simon Wiederhold, 2013. "Nachfrageorientierte Innovationspolitik: Bestandsaufnahme und ökonomische Bewertung," ifo Beiträge zur Wirtschaftsforschung, Ifo Institute - Leibniz Institute for Economic Research at the University of Munich, number 51.
  115. Jeffrey Clemens, 2013. "The Effect of U.S. Health Insurance Expansions on Medical Innovation," NBER Working Papers 19761, National Bureau of Economic Research, Inc.
  116. David Besanko & David Dranove & Craig Garthwaite, 2016. "Insurance and the High Prices of Pharmaceuticals," NBER Working Papers 22353, National Bureau of Economic Research, Inc.
  117. Stefano DellaVigna & Joshua M. Pollet, 2005. "Attention, Demographics, and the Stock Market," NBER Working Papers 11211, National Bureau of Economic Research, Inc.
  118. Stefano DellaVigna & Joshua M. Pollet, 2007. "Demographics and Industry Returns," American Economic Review, American Economic Association, vol. 97(5), pages 1667-1702, December.
  119. Stefano DellaVigna & Joshua M. Pollet, 2009. "Capital Budgeting vs. Market Timing: An Evaluation Using Demographics," NBER Working Papers 15184, National Bureau of Economic Research, Inc.
  120. Clemens, Jeffrey, 2014. "Implications of Physician Ethics, Billing Norms, and Service Cost Structures for Medicare's Fee Schedule," MPRA Paper 73392, University Library of Munich, Germany.
  121. Simon Wiederhold, 2009. "Government Spending Composition in a Simple Model of Schumpeterian Growth," Jena Economic Research Papers 2009-101, Friedrich-Schiller-University Jena.
  122. Lundin Douglas & Ramsberg Joakim, 2008. "Dynamic Cost-Effectiveness: A More Efficient Reimbursement Criterion," Forum for Health Economics & Policy, De Gruyter, vol. 11(2), pages 1-17, November.
  123. Adrian Towse, 2007. "If it ain't broke, don't price fix it: the OFT and the PPRS," Health Economics, John Wiley & Sons, Ltd., vol. 16(7), pages 653-665.
  124. Slavtchev, Viktor & Wiederhold, Simon, 2014. "Does the Technological Content of Government Demand Matter for Private R&D? Evidence from US States," IWH Discussion Papers 10/2014, Halle Institute for Economic Research (IWH).
  125. Jay Bhattacharya & Mikko Packalen, 2008. "Is Medicine an Ivory Tower? Induced Innovation, Technological Opportunity, and For-Profit vs. Non-Profit Innovation," NBER Working Papers 13862, National Bureau of Economic Research, Inc.
  126. Raphaël Godefroy, 2010. "The birth of the congressional clinic," PSE Working Papers halshs-00564921, HAL.
  127. Cohen, Wesley M., 2010. "Fifty Years of Empirical Studies of Innovative Activity and Performance," Handbook of the Economics of Innovation, Elsevier.
  128. IIZUKA Toshiaki & UCHIDA Gyo, 2016. "Promoting Innovation in Small Markets: Evidence from the market for rare and intractable diseases," Discussion papers 16036, Research Institute of Economy, Trade and Industry (RIETI).
  129. Margaret E. Blume-Kohout & Neeraj Sood, 2008. "The Impact of Medicare Part D on Pharmaceutical R&D," NBER Working Papers 13857, National Bureau of Economic Research, Inc.
  130. Michael Kremer & Christopher Snyder, 2015. "Preventives Versus Treatments," NBER Working Papers 21012, National Bureau of Economic Research, Inc.
  131. Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
  132. [multiple or corporate authorship]., 2006. "Boosting innovation and productivity growth in Europe: the hope and the realities of the EU's "Lisbon agenda"," LSE Research Online Documents on Economics 57956, London School of Economics and Political Science, LSE Library.
  133. Francesco Laforgia & Fabio Montobbio & Luigi Orsenigo, 2007. "IPRs, technological and industrial development and growth: the case of the pharmaceutical industry," KITeS Working Papers 206, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised Oct 2007.
  134. Hulya Ulku, 2004. "R&D, Innovation, and Economic Growth; An Empirical Analysis," IMF Working Papers 04/185, International Monetary Fund.
  135. Xiao, Sheng & Zhao, Shan, 2012. "Financial development, government ownership of banks and firm innovation," Journal of International Money and Finance, Elsevier, vol. 31(4), pages 880-906.
  136. Königbauer, Ingrid, 2006. "Dealing with Rising Health Care Costs: The Case of Pharmaceuticals," Munich Dissertations in Economics 5640, University of Munich, Department of Economics.
  137. Thijs Dekker & Herman R.J. Vollebergh & Frans P. de Vries & Cees A. Withagen, 2009. "Inciting Protocols - How International Environmental Agreements Trigger Knowledge Transfers," Tinbergen Institute Discussion Papers 09-060/3, Tinbergen Institute, revised 29 Nov 2010.
  138. Sauré, Philip, 2017. "Time-intensive R&D and unbalanced trade," European Economic Review, Elsevier, vol. 91(C), pages 229-244.
  139. Viktor Slavtchev & Simon Wiederhold, 2012. "Technological Intensity of Government Demand and Innovation," Ifo Working Paper Series Ifo Working Paper No. 135, Ifo Institute - Leibniz Institute for Economic Research at the University of Munich.
  140. van den Bijgaart, Inge, 2016. "Essays in environmental economics and policy," Other publications TiSEM 298bee2a-cb08-4173-9fe1-8, Tilburg University, School of Economics and Management.
This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.